HeartSciences receives FDA clearance for MyoVista wavECG without AI
The 510(k) decision covers resting ECG use in adults and children, but HeartSciences has set no device launch date.
Adrian Kessler
A U.S. regulatory hurdle has cleared for a cardiac device its maker does not plan to sell yet, after HeartSciences Inc. NASDAQHSCS said on Tuesday that the FDA granted 510(k) clearance for its MyoVista wavECG. The 12-lead device can acquire and interpret resting ECG signals, but the clearance excludes the AI algorithm HeartSciences says it needs before commercialization.
The clearance, identified by the company as K260005, covers adult and pediatric patients in hospitals and other healthcare facilities. Its interpretive statements are advisory to clinicians; HeartSciences has made no commitment to a launch date for the device.
HeartSciences is a small Texas medical technology company developing electrocardiography hardware and cloud software for clinical workflows. Its separate MyoVista Insights platform manages ECG records and is the company's stated commercial focus.
HeartSciences shares NASDAQHSCS closed at US$3.77, down 13.53 per cent, on Nasdaq at 4 p.m. EDT on Oct. 6. The company also expects its proposed business combination with Fortitude Mining Holdings, Inc. to close in the fourth quarter of 2026, subject to conditions including HeartSciences shareholder approval.
AI Algorithm Remains Outside The Clearance
The FDA decision covers a conventional resting electrocardiograph, according to HeartSciences' Oct. 6 release. The company said it separated the device submission from its impaired cardiac relaxation AI algorithm after updated guidance from the American Society of Echocardiography on assessing left ventricular diastolic dysfunction.
That split leaves the diagnostic ambition outside the newly cleared indication. HeartSciences' Oct. 6 release gives no date for clearance of the AI algorithm and says the company does not intend to commercialize the hardware without one. Its product page describes the device as built to host AI algorithms, while listing the impaired cardiac relaxation model as pre-FDA.
The company said the clearance broadens the options it can evaluate for the device and its related intellectual property. It did not announce a customer order, revenue forecast or U.S. shipment schedule with the decision.
"Our commercial focus remains on MyoVista Insights, but clearance makes the device and the intellectual property behind it a more readily realizable asset, and we will take the time to consider the best route to realizing that value," HeartSciences chief executive Andrew Simpson said in the release.
That distinction leaves the hardware's immediate financial effect undefined: regulatory clearance applies to the resting ECG function, while the proposed commercial version depends on a separate AI decision. It also means the MyoVista Insights software business and the newly cleared device are at different stages of deployment.
Read more: Telix Pharmaceuticals Limited reports first US Pixclara doses for glioma imaging
ECG Peers Have Different Cleared Uses
HeartBeam, Inc. NASDAQBEAT said in December 2025 that the FDA cleared its software to synthesize a 12-lead ECG from a portable recorder for adult arrhythmia assessment. Its stated use is manual assessment of a defined group of non-life-threatening rhythms, including atrial fibrillation, rather than replacement of a standard diagnostic 12-lead ECG.
Read more: HeartBeam receives FDA breakthrough status for heart attack assessment
iRhythm Technologies, Inc. NASDAQIRTC describes its Zio service as wearable ambulatory ECG monitoring with AI-assisted analysis and clinical review. The use differs from a resting ECG recorded in a healthcare facility, so the three companies' regulatory clearances cover distinct clinical workflows.
For a dated sector market snapshot, iRhythm shares NASDAQIRTC closed at US$107.20 on Nasdaq at 4 p.m. EDT on Oct. 6.
HeartSciences said its proposed Fortitude combination is expected to close in the fourth quarter of 2026 if shareholders approve it and other conditions are met. That transaction is the company's next stated calendar milestone; the release gives no date for an AI clearance or for MyoVista wavECG sales.
